English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 22 June 2018, 11:58 JST
Share:
    

Source: Eisai
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN)

TOKYO, June 22, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for the first time for membership in the MSCI Japan Empowering Women Index (WIN), an index developed for environmental, social and governance (ESG) investment. This index is one of the indices adopted by the Government Pension Investment Fund (GPIF) for selecting investments based on ESG initiatives as an indicator of non-financial value.

The MSCI Japan Empowering Women Index (WIN) is developed by MSCI Inc., the industry leader in ESG research who offers various tools to support the investment decisions of major investors around the world. For the MSCI Japan Empowering Women Index, MSCI selects industry leading companies in terms of attracting, retaining and promoting women, as well as advancing gender diversity. Selection is based on data regarding female employment disclosed according to the Act on Promotion of Women's Participation and Advancement in the Workplace as well as information publicly disclosed by companies such as company policy on gender diversity. In 2012, Eisai issued the Eisai Diversity Declaration, and implements various initiatives aimed at developing an organizational climate for utilizing diverse values as well as promoting the advancement of women.

Eisai has also been selected for inclusion in the FTSE Blossom Japan Index as well as the MSCI Japan ESG Select Leaders Index, which now means that Eisai has been selected for all three ESG indices for Japanese stocks adopted by the GPIF.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.

Contact:
Media Inquiries: 
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
2025年7月16日 14時40分 JST
エーザイ、抗アミロイドβ抗体レカネマブの創薬研究が「第 9 回バイオインダストリー大賞」を受賞
Wednesday, 16 July 2025, 14:50 JST
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
Monday, 14 July 2025, 10:20 JST
"URECE" (Dotinurad) Launched in China as a treatment for Gout
2025年7月14日 9時00分 JST
エーザイ、痛風治療剤「URECE」(一般名:ドチヌラド)を中国において新発売
2025年7月9日 14時50分 JST
エーザイ、厚生労働省の中央社会保険医療協議会による「レケンビ」の費用対効果評価について
More news >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575